{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:31:20Z","timestamp":1784752280492,"version":"3.55.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ad.2013.09.013","type":"journal-article","created":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T20:47:02Z","timestamp":1387226822000},"page":"802-803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Rapamicina t\u00f3pica al 0,2% para el tratamiento de angiofibromas faciales y m\u00e1culas hipomelan\u00f3ticas en la esclerosis tuberosa"],"prefix":"10.1016","volume":"105","author":[{"given":"N.","family":"Kn\u00f6pfel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mart\u00edn-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bauza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Herv\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2013.09.013_bib0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1749-6632.2009.05117.x","article-title":"The tuberous sclerosis complex","volume":"1184","author":"Orlova","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ad.2013.09.013_bib0010","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11910-012-0269-4","article-title":"Molecular therapies for tuberous sclerosis and neurofibromatosis","volume":"12","author":"Franz","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.ad.2013.09.013_bib0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/09546634.2010.489598","article-title":"Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin","volume":"23","author":"Kaufman McNamara","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2013.09.013_bib0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","article-title":"Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: A double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin","volume":"12","author":"Koenig","year":"2012","journal-title":"Drugs R D"},{"key":"10.1016\/j.ad.2013.09.013_bib0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-0960.2011.00837.x","article-title":"Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: A pilot study of four patients","volume":"53","author":"Foster","year":"2012","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ad.2013.09.013_bib0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ad.2011.02.019","article-title":"Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis","volume":"103","author":"Valer\u00f3n-Almaz\u00e1n","year":"2012","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2013.09.013_bib0035","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1468-3083.2011.04212.x","article-title":"Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis associated facial angiofibroma","volume":"26","author":"Salido","year":"2012","journal-title":"J EurAcad Dermatol Venereol"},{"key":"10.1016\/j.ad.2013.09.013_bib0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/archderm.148.1.138","article-title":"A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex","volume":"148","author":"Wataya-Kaneda","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2013.09.013_bib0045","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/jcp.20421","article-title":"Negative regulation of melanogenesis by phospholipase D1 through mTOR\/p70 S6 kinase 1 signaling in mouse B16 melanoma cells","volume":"205","author":"Ohguchi","year":"2005","journal-title":"J Cell Physiol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731013003797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731013003797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:02:18Z","timestamp":1757552538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731013003797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0001731013003797"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2013.09.013","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapamicina t\u00f3pica al 0,2% para el tratamiento de angiofibromas faciales y m\u00e1culas hipomelan\u00f3ticas en la esclerosis tuberosa","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2013.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y AEDV. All rights reserved.","name":"copyright","label":"Copyright"}]}}